SARS-CoV-2, nje na-akpata COVID-19, enweela nnukwu mmetụta na ahụike mmadụ n'ụwa niile;na-efe efe ọtụtụ mmadụ;na-eme ka ọrịa siri ike na-ejikọta ya na ogologo oge ahụike sequelae;na-ebute ọnwụ na oke ọnwụ, karịsịa n'etiti ndị agadi na ndị na-adịghị ike;na-akwụsị ọrụ nlekọta ahụike oge niile;na-akpaghasị ọrụ nlekọta ahụike oge niile;nkwụsị nke njem, ịzụ ahịa, agụmakwụkwọ na ọtụtụ ọrụ ọha mmadụ ndị ọzọ;na inwe mmetụta na-adịghị mma na ahụike anụ ahụ na nke uche ndị mmadụ.

Ụdị mkpụrụ ndụ ihe nketa nke SARS-CoV-2 na-apụta ma na-ekesa gburugburu ụwa n'oge ọrịa COVID-19.

Maka nchọpụta nanjirimaraN'ụdị dị iche iche sitere na UK, Brazil, South Africa na India, ndị sayensị Foregene ewepụtala ngwa nchọpụta ọhụrụ maka ha.

Ngwa a na-eji teknụzụ RT PCR Real-time (rRT-PCR) maka nchọpụta qualitative nke SARS-CoV-2 na njirimara variant lineages nucleic acids na ụmụ mmadụ nasopharyngeal ma ọ bụ oropharyngeal swab samples, dị ka SARS-CoV-2 B.1.1.7 lineage (AUK), B.1.351 lineage (B.1.351 lineage). ).

Foregene SARS-CoV-2 Variant kit is so competitive , Tụnyere ụfọdụ Brand ọzọ, anyị Kit adịghị mkpa iji nucleic acid mmịpụta ngwa na usoro, anyị nwere ike iji anyị Direct PCR technology (otu nzọụkwụ) maka nchọpụta na-achọpụta variant mutate SARS-CoV-2 B.1.1.7 lineage (UK), na B.1.1 lineage (UK), B.1.1 lineage (UK), na B.1.1 lineage. P.1 usoro ọmụmụ (BR).ngwa ngwa .

Usoro ngwaahịa

Ugbu a ụlọ ọrụ ule Morocco anabatala ngwa usoro ndị a, na-atụ anya isonyere ndị na-ekesa ọhụrụ sitere n'akụkụ ụwa niile.

SARS-CoV-2 dị iche iche ahịrị na saịtị mutant